Medizintechnik acquires BSD-2000/3D/MR integrated hyperthermia system

NewsGuard 100/100 Score

BSD Medical Corporation (NASDAQ: BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, today announced that Dr. Sennewald Medizintechnik GmbH (Medizintechnik) has purchased BSD Medical's BSD-2000/3D/MR Hyperthermia System (BSD-2000/3D/MR). This BSD-2000/3D/MR system is an integration of BSD's advanced regional hyperthermia system with a Magnetic Resonance (MR) Imaging System from Siemens Healthcare. This BSD-2000/3D/MR System is equipped with an innovative array of MR compatible applicators: the Sigma Eye MR applicator for the treatment of adults, the Sigma 40 MR applicator for the treatment of small adults and older children, and the Sigma 30 MR applicator for the treatment of younger children down to the age of 3.

The BSD-2000/3D/MR is an integration of the world's most sophisticated hyperthermia therapy system with magnetic resonance imaging. It introduces a revolutionary new use of magnetic resonance imaging, expanding MRI utilization from its traditional role in diagnostic imaging to real-time imaging and monitoring of cancer treatments. The magnetic resonance images are color graded to show temperature changes in the treatment area during hyperthermia therapy. The BSD-2000/3D/MR System was developed in a collaborative effort with Siemens Healthcare AG, Erlangen, Germany. The BSD-2000/3D/MR has received CE Marking approval.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study explores parents' struggle with children's avid eating behaviors